If you’ve been waiting on your SBIR application since late 2025, the wait is over.
On April 13, 2026, President Trump signed S. 3971 — the Small Business Innovation and Economic Security Act — into law. After a six-month freeze that left thousands of small businesses in limbo, the SBIR and STTR programs are officially reauthorized through September 30, 2031.
Here’s what that means for you, and what you need to do right now.
What happened, and why it matters
The SBIR/STTR programs expired on September 30, 2025 when Congress failed to pass reauthorization before the deadline. It was the longest disruption in the programs’ 43-year history. NIH canceled active solicitations. NSF paused Project Pitch submissions. DoD shelved pre-solicitation topic lists. More than $4 billion in annual funding was frozen.
For early-stage biotech and medtech companies, this wasn’t just an inconvenience — it meant months of delayed R&D, stalled hiring plans, and runway burned on dilutive capital that shouldn’t have been necessary.
That’s done now. The programs are back, and the window to act is open.
3 major changes you need to know
1. A brand new multi-million dollar funding mechanism
The reauthorization created something that didn’t exist before: the Strategic Breakthrough Award. With institute specific waivers, total funding ranges between $3,000,000 – $15,000,000!
To qualify, you need at least one prior Phase II award and 100% matching funds from private capital or non-SBIR government sources. It’s a serious bar — but for companies that meet it, this is a transformational new pathway. Think of it as a bridge between SBIR Phase II and a full government contract or commercial scale-up.
Most consultants and applicants haven’t fully absorbed this yet. If you have a Phase II under your belt and strong investor relationships, this is worth a serious conversation.
2. A 9-proposal submission cap starting FY2027
Beginning in fiscal year 2027, every SBIR/STTR agency will limit how many proposals a single company can submit per year. The intent is clear: Congress wants to shut down “SBIR mills” — companies that have historically submitted dozens of proposals across every agency, regardless of fit.
What this means for you: it’s time to alter your approach to grant applications. It’s about structuring a long-term, multi submission granting strategy in order to maximize potential to win, while taking into consideration the 9 cap limitation. Prioritization and planning are key drivers of success. The companies that will win in the new environment are the ones that apply strategically — fewer proposals, better targeted, stronger commercial narratives.
This is actually good news for first-time and early-stage applicants who’ve been competing against high-volume submitters. The playing field is getting more level.
3. NIH will now accept Direct-to-Phase II STTR applications
This is a significant change for companies with more developed technology. Previously, NIH STTR applicants typically had to go through Phase I before accessing Phase II funding. The new rules open up a Direct-to-Phase II pathway for STTR, which NIH already offered for SBIR.
If your technology is past the proof-of-concept stage and you have a strong research institution partner, a Direct-to-Phase II STTR application could get you to significant funding faster.
The bottom line
The six-month freeze set a lot of companies back. But it also created an opportunity: the companies that move quickly and strategically now will have an advantage over those still catching up.
FreeMind Group helps early-stage life science companies navigate exactly this — identifying the right funding mechanisms, matching your science to the right institutes, and writing proposals that score. If you want to talk through your eligibility or your strategy for the new landscape, book a call with our team.
The window is open. Don’t miss it.
